Clinical Trial Update: Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails [Phase 3]

View source ↗

Summary

A Phase 3 trial of NAB001 for mild-to-moderate toenail onychomycosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Onychomycosis

Drugs mentioned

• NAB001

Snippet

Sponsor: Promius Pharma, LLC | Conditions: Onychomycosis | Phase 3 | Status: TERMINATED